Research that was conducted recently to identify the effects of LSD has been reported in the “Neuropsychopharmacology” journal. The discoveries will be used to plan clinical trials that examine the use of LSD in patients with various psychiatric disorders.
Prior research had discovered that LSD could be a treatment for some mental conditions when used in combination with psychotherapy. However, these studies compared LSD doses to placebo. Researchers for the new study focused on testing the effects of LSD in different doses.
Matthias E. Liechti, a researcher from the University Hospital Basel, stated that the group or researchers wanted to produce more clinical data on LSD for its use as a medication, adding that their study provided information on the serious effects of the psychedelic when used in different doses. Liechti stated that this information would be helpful in selecting the right dosage amounts for future trials evaluating patients who suffer from depression and anxiety.
In the course of six experimental sessions that were conducted in a controlled lab setting under double-blind conditions, eight women and eight men received a high LSD dose that was combined with ketanserin and four different LSD doses. The researchers discovered that when compared to placebo, all four LSD doses — 25, 50, 100 and 200 micrograms — were tied to experiences of visionary restructuralization and oceanic boundlessness. However, only the 50-, 100- and 200-microgram LSD doses were linked to the experience of losing one’s sense of self, commonly referred to as ego death.
The researchers also found proof of a ceiling effect. While there was no difference recorded in positive subjective effects between the 100- and 200-microgram doses of LSD, positive effects were found to increase from the lowest dose to 100 micrograms. Researchers also discovered that the 200-microgram LSD dose was the only dose that considerably grew anxiety ratings when compared with the placebo. The dose also induced considerably greater ego dissolution.
Additionally, the researchers discovered that doses of LSD that were 100 and 200 micrograms increased heart rate while doses that were 50 micrograms or higher increased blood pressure. The researchers noted that in the LSD psychedelic dose range, good effects mainly occurred when a dose of between 30 to 100 micrograms was administered. In contrast, they found that an increase in anxiety and ego dissolution occured when the LSD dosage is above 100 micrograms. They also found that administering ketanserin led to considerable reduction in the effects of LSD.
The World Health Organization estimates that approximately 700 million individuals from around the globe suffer from mental health issues, eating disorders or addictions. The unmet treatment needs of all these people may be the reason why companies such as Cybin Corp. (NEO: CYBN) (OTCQB: CLXPF) are hard at work developing novel drug delivery mechanisms and drug candidates from psychedelic substances.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
